No quarterly revenue total was found in MIRA Pharmaceuticals, Inc.'s SEC filings.
MIRA Pharmaceuticals, Inc. (MIRA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.21M
+21.4% vs year-ago quarter
Operating cash flow
$-1.21M
-50.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.03
+66.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
42.02M
+120.4% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MIRA (Nasdaq)
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1904286
- Former names
- Mira1a Therapeutics, Inc. (until May 2, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$1.2M | -$1.2M | -$6.0M | -$1.1M | -$1.5M |
| Diluted EPS | -$0.03 | -$0.03 | — | -$1.18 | -$0.09 |
| Operating cash flow | -$1.2M | -$1.2M | -$1.1M | -$1.1M | -$799,651 |
| Total assets | $8.2M | $9.5M | $11.1M | $7.6M | $868,318 |
| Total liabilities | $40,823 | $114,761 | $702,068 | $83,926 | $298,459 |
| Stockholders' equity | $8.2M | $9.3M | $10.4M | $7.5M | $569,859 |
| Cash and investments | $8.1M | $9.4M | $11.0M | $7.5M | $730,475 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 17, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 16, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 1, 2026 | Sep 1, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 198 MIRA Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.